HERE And Sigfox Join Forces to Create Global IoT Location Service for Logisitics and Supply Chain Sectors
HERE Technologies and Sigfox today announced a partnership to develop and deploy a global location service that will open new opportunities for IoT applications, particularly in supply chain and logistics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180530005612/en/
By integrating global coverage of wifi hotspots from HERE with the Sigfox worldwide network and geolocation engine, industry and consumers will be able to locate their assets everywhere, both indoors (including inside factories warehouses and other buildings) and outdoors, without any additional infrastructure, regardless of the size and quantity of assets.
The use of IoT asset tracking solutions in the global supply chain and logistics sector could create $1.9 trillion of economic value, according to Cisco and DHL, the world’s largest logistics provider. Current Real Time Location Services (RTLS) solutions are not always viable due to the high cost sensitivity and the short battery life constraints. This partnership also expands asset tracking opportunities for companies that could not previously afford geolocation services. The unique combination of both HERE and Sigfox technologies and their worldwide footprint enables clients to not only locate their assets, but to collect useful data that will help them to optimize their flows, ensure better transport conditions and increase service reliability. Use cases currently in live phase include air transport, luggage/trolley management, location of stolen/missing cars cars, industrial asset management and location of shipping containers.
«Our partnership with Sigfox reinforces HERE as a major player in IoT» said Christophe Hamaide, Senior Account Executive at HERE. « The HERE Location Suite references billions of Wi-Fi hotspots, and through this joint initiative, we will be able to pinpoint the location of millions of connected objects all around the world in the coming years. »
“This partnership is another major step to accomplish Sigfox’s ambitious vision to become the most competitive provider of industrial data in IoT” said Laetitia Jay, Chief Marketing Officer at Sigfox. “Locating assets while guaranteeing the lowest total cost of ownership of the solution is a key driver for logistics and supply chain industry to benefit from massive IoT business impact.”
For more information on Sigfox, visit Twitter or LinkedIn.
For more information on HERE Technologies, visit www.here.com
* http://www.businessinsider.fr/us/asset-tracking-in-the-supply-chain-and-logistics-2016-9
About Sigfox
Sigfox is the world’s leading IoT service
provider thanks to its global network that connects billions of devices
to the Internet while consuming as little energy as possible, as simply
as possible. Sigfox’s unique approach to device-to-cloud communications
addresses the three greatest barriers to global IoT adoption: cost,
energy consumption, and global scalability.
Today, the network is present in 45 countries and on track to cover 60 by 2018. With millions of objects connected and a rapidly growing partner ecosystem, Sigfox empowers companies to move their business model towards more digital services. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in Labège near Toulouse, France’s “IoT Valley”. Sigfox also has offices in Paris, Madrid, Munich, Boston, San Francisco, Dubai, Singapore, Sao Paulo and Tokyo.
About HERE Technologies
HERE, the Open Location Platform
company, enables people, businesses and cities to harness the power of
location. By making sense of the world through the lens of location we
empower our customers to achieve better outcomes – from helping a city
manage its infrastructure or a business optimize its assets to guiding
drivers to their destination safely. To learn more about HERE, including
our new generation of cloud-based location platform services, visit http://360.here.com
and www.here.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530005612/en/
Contact information
Media Contacts:
Sigfox – Elan Edelman
sigfoxfrance@elanedelman.com
Pauline
Persyn - 06 20 43 84 67
Luisa Vittadini - 01 86 21 50 51
or
HERE
- Agence AxiCom
Constance Falourd – 01 56 02 68 25
constance.falourd@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGA Company Named ANV Group Holdings Ltd.5.12.2025 14:00:00 EET | Press release
AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV Specialty, Risico, Collegiate, ANV Nordic, Arc Legal, Qualis, and Abacus. These businesses provide diverse risk and insurance coverages including cyber excess and surplus (E&S), directors and
Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom